Eleven-Week Polarized vs Pyramidal Intensity Distribution in National Elite Rowers: Polarized Not Superior
Participants
n=14 national elite male rowers (age 20 ± 2 years; VO2max 66 ± 5 mL/min/kg), split into a pyramidal (PYR) and a polarized (POL) group
Protocol
11-week preparation period; total and rowing volume matched between groups
Zone 1 (below first lactate threshold) clamped at ~93% of training time in both groups; the groups differed only in how the remainder was split between zone 2 (between thresholds) and zone 3 (above the second threshold)
Actual distribution: POL zone 3 = 6 ± 3% vs PYR 2 ± 1% (p<0.005); POL zone 2 = 1 ± 1% vs PYR 3 ± 2% (p<0.05); zone 1 = 94 ± 3% vs 93 ± 2% (p=0.37)
Polarization-Index = log(%Z1 × %Z3 / %Z2): POL 3.0 ± 0.7 vs PYR 1.9 ± 0.4 a.u. (p<0.01)
Outcomes: average power in a 2000 m ergometer test (P2000m), power at 4 mmol/L blood lactate (P4[BLa]), VO2max
Key Findings
P2000m did not change significantly in either group: PYR +1.5 ± 1.7% (p=0.06), POL +1.5 ± 2.6% (p=0.26)
VO2max did not change: +1.7 ± 5.6% (p=0.52) and +0.6 ± 2.6% (p=0.67)
P4[BLa]: small increase in PYR only (+1.9 ± 4.8%, p=0.37) vs −0.5 ± 4.1% (p=0.77) in POL — neither significant
No between-group difference in any performance measure
Authors' reading: POL was not superior to PYR, possibly because zone 1 was so high (~93%) and so similar in both groups
Practical Application
In 14 national elite male rowers (VO2max 66), 11 weeks of polarized (94/1/6 % in zones 1/2/3) versus pyramidal (93/3/2 %) training with matched volume produced no significant change in 2000 m ergometer power in either group (+1.5% each) and no between-group difference in P2000m, P4[BLa] or VO2max — polarized was not superior to pyramidal here (Treff 2017).
When the easy volume already dominates (~93% below the first lactate threshold), shuffling the last few percent between threshold and above-threshold work did not change the outcome over 11 weeks in these rowers.
Not from this paper; the base's own practice: choose pyramidal vs polarized by the phase and the athlete's tolerance rather than expecting one to win outright; pyramidal blocks are the norm in preparation periods, polarized closer to competition.
Not from this paper: the base's larger polarized-vs-threshold comparison in trained mixed endurance athletes (REF-303) found polarized superior — the two results differ in population, comparator and how much zone 2 the non-polarized arm carried (35 % there vs 3 % here).
Limitations
n=14 in two groups of national-level rowers; underpowered for small differences, and the within-group P2000m changes (+1.5%) did not reach significance either.
The contrast between the two distributions was small (zone 3: 6% vs 2%; zone 2: 1% vs 3%) because zone 1 was clamped near 93% — the study tests a narrow question.
Rowing ergometer outcomes in a preparation period; nothing about competition results or longer time frames.
Intensity zones by heart rate (Z1, Z2) and interval duration (Z3); no power-based distribution.
How this entry was checked and changed
Why this level
regraded 2026-09-27 from B+: controlled parallel trial, n=14, two small groups
Content correction 2026-09-27
"Training distribution NOT strictly polarized — 60-70% low, 20-30% threshold, 10-15% high", "performance equivalent to polarized groups", "individual variation ±15%", "training age 10+ years" -> invented; the abstract describes a controlled POL-vs-PYR comparison with zone 1 clamped at ~93% and no significant performance change or group difference.
Title "German World-Class Rowers: Polarized or Not?" -> the paper's finding (POL not superior to PYR); Type "case study" -> controlled intervention; Level B+ -> B; Tier 5 -> Tier 3 (national elite, VO2max 66); Sport "cycling, rowing" -> rowing.
"Well-trained amateurs (FTP 280-350 W) should shift to 65-70/15-20/10-15" and "beginners strictly 75/10-15/10-15" -> house advice with invented numbers; removed.
REF-079 was an empty stub and is now filled: it is a C+ narrative review (Hydren & Cohen 2015), so pointers for polarized-vs-other evidence now lead with the trial REF-303.